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After treatment for high-grade cervical intraepithelial neoplasia
(CIN) failure rates of 5–15% have been observed (Gunasekera
et al, 1990; Benedet et al, 1992; Alvarez et al, 1994; Mitchell et al,
1998). One of the drawbacks of close cytological follow-up after
treatment is that many women present with abnormal cytology but
in only about 40–60% of them an underlying CIN lesion is present,
indicating high sensitivity but low specificity for post-treatment
CIN (Bigrigg et al, 1994; Bollen et al, 1999). Colposcopic examin-
ation, as an adjunct to cytology, is often inadequate because of
the difficulty in interpreting features of the post-treatment cervix,
resulting in unnecessary diagnostic procedures (Bigrigg et al,
1994). 
According to the Dutch guidelines, as formulated by the Dutch
Society of Cervical Pathology and Colposcopy in 1995, follow-up
after treatment for CIN 2 or 3 (moderate to severe dysplasia)
consists of cytological follow-up at 6, 12 and 24 months after
treatment. Only in the case of an abnormal cervical smear is colpo-
scopic examination indicated (Heintz, 1995; Bollen et al, 1999).
After three consecutive negative smears women return to the
cervical cancer screening programme. In some other European
countries monitoring also consists of cytological follow-up
(Duncan, 1992; Chua and Hjerpe, 1997; Mann et al, 1999). For
instance, in the UK a total of six smears within 5 years of
follow-up are recommended before routine recall. However, in
spite of these national guidelines the follow-up policies still vary
from centre to centre, indicating a need for evaluation and better
implementation. 
It is assumed that effective treatment for CIN lesions results in
the eradication of the high-risk human papilloma virus (HPV)
infection present before treatment (Elfgren et al, 1996). Persistent
infection with high-risk HPV types is required for the develop-
ment and progression of primary CIN lesions (Remmink et al,
1995; Ho et al, 1998; Nobbenhuis et al, 1999). High-risk HPV is
also often present in post-treatment CIN (Chua et al, 1997). 
In this observational study we evaluated the rationale for our
current follow-up policy, and whether addition of high-risk HPV
testing contributes to a better risk-assessment of post-treatment
CIN. 
PATIENTS AND METHODS 
From 1990–96, 184 women diagnosed with CIN 2 or 3 (moderate
and severe dysplasia) at the colposcopy outpatient clinic of the
University Hospital Vrije Universiteit in Amsterdam and consec-
utively treated by cone biopsy or colposcopic guided large loop
excision of the transformation zone (LLETZ) were included in this
study. All fulfilled the following inclusion criteria: an adequate
HPV sample (b-globin PCR-positive) at initial treatment; at least
one adequate HPV sample after treatment; no previous history of
cervical pathology; no prenatal DES (diethylstilboestrol) expo-
sure; and no concomitant cancer. The median follow-up time was
24 months (range 3–76 months). The study protocol was approved
by the ethics review board of the hospital. 
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Cervical cytology and HPV testing 
In this prospective, observational study post-treatment follow-up
was performed by cervical cytology and HPV testing at 3, 6, 9, 12
and 24 months after initial treatment. Since high-risk HPV testing
was used for the evaluation of the current follow-up policy, the
test results were blinded until the analysis. Cervical scrapes were
obtained using a cervex® brush (International Medical Products,
Zutphen). After a smear was made on a glass slide the brush was
placed in a buffer solution (PBS) and sent to the laboratory for
HPV detection (Walboomers et al, 1995). 
Cervical smears were classified according to the KOPAC classi-
fication, the standard classification in The Netherlands (Hanselaar,
1995). Smears were cytomorphologically classified as Pap 1
(normal), Pap 2 (very mild dyskaryosis), Pap 3a (mild to moderate
dyskaryosis), Pap 3b (severe dyskaryosis), Pap 4 (suspected of
carcinoma in situ) and Pap 5 (suspected of at least micro-invasive
carcinoma). According to the guidelines, colposcopic examination
including sampling for histological verification of suspect lesions
was only performed in case of a cytomorphologically abnormal
smear (³ Pap 3a, mild dyskaryosis or worse) (Heintz, 1995;
Helmerhorst and Wijnen, 1998; Bollen et al, 1999). All histolo-
gical samples were reviewed by an expert pathologist who was
unaware of the clinical findings. 
A b-globin PCR was performed to ascertain the quality of the
target DNA. HPV testing was performed by EIA PCR using HPV-
general-primer-mediated PCR with the general primers GP 5+/6+.
All 14 high-risk HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56,
58, 59, 66 and 68) were tested for in one assay. In addition, the PCR
amplification products were analysed for individual high-risk HPV
types. This test has been described earlier and clinically validated
(Remmink et al, 1995; Jacobs et al, 1997; Nobbenhuis et al, 1999). 
Study endpoint 
The study endpoint was post-treatment CIN 2/3 defined as a
histologically confirmed CIN 2 or 3 lesion after previous treat-
ment. Follow-up ended when patients reached this endpoint.
According to the Dutch guidelines women returned to the popul-
ation-based cervical cancer screening programme after three
consecutive negative cervical smears within 24 months after
treatment, since these women are considered not to have an
elevated risk for post-treatment CIN 2 or 3 (Heintz, 1995;
Helmerhorst and Wijnen, 1998). 
Statistical analysis 
We used two-by-two tables to assess the diagnostic value for post-
treatment CIN 2/3 of a high-risk HPV test and a cervical smear at
3, 6, 9, 12 and 24 months after initial treatment, respectively. In
these analyses women without a suspected cervical lesion on
colposcopic examination, or with CIN 0 (no CIN) or CIN 1 (mild
dysplasia) in the biopsy were considered as ‘negative’. For these
analyses, the last observations were carried forward for women
who had already reached the endpoint and women who returned
to their general practitioner before 24 months of follow-up.
Women with repeated negative cervical smears were considered
to have a colposcopically normal cervix. The McNemar test was
used to identify a significant difference in HPV testing and
cytology for women with post-treatment CIN 2/3 at different
time-points. 
RESULTS 
Characteristics of the study group 
The mean age at baseline was 34 years (range 21–70 years). Of the
included 184 women, 152 were treated by LLETZ and 32 women
by cone biopsy (see Table 1). At initial treatment three women
(1.6%) with a CIN 3 lesion had negative high-risk HPV tests, both
in the cervical smear and biopsy, and remained negative during
follow-up after treatment. HPV type 16 was the most prevalent
high-risk HPV type at baseline, accounting for 116 of the 181
(64.1%) high-risk HPV-positive women. After treatment, high-risk
HPV remained detected in 48 of the 184 women (26.1%). Post-
treatment CIN 2/3 was seen in 29 (15.8%) women with a median
time until diagnosis of 6 months (range 3–39 months). 
Post-treatment CIN 2/3 
The characteristics of the 29 women with post-treatment CIN 2/3 are
presented in Table 2. All women with post-treatment CIN 2/3 had
CIN 3 at initial treatment and the mean age was 35 years (range
21–58 years). Seventy-two percent (21 of 29) of the cases were
diagnosed within 1 year after treatment. Three months after initial
treatment the high-risk HPV test was positive in 27 of the 29 cases
(93%). The most prevalent high-risk HPV type was HPV type 16,
accounting for 81% (22 of 27) of the HPV types. In two women
with post-treatment CIN 2/3 no high-risk HPV could be demon-
strated in the biopsy or additional treatment tissue. One of them
(patient 19) had a high-risk HPV positive test 3 months after treat-
ment and cleared this infection before 6 months of follow-up. In
26 of the 29 (89.7%) women with post-treatment CIN 2/3 the same
high-risk HPV type could be detected in the post-treatment lesion
as at initial treatment. This could indicate that the treatment did not
result in eradication of the virus. Only one woman (patient 21)
with an initial HPV type 16 infection cleared this type and
acquired HPV type 58, 19 months after treatment. Two women,
one with CIN 2 (patient 19) and one with CIN 3 (patient 20), had a
high-risk HPV-negative test at post-treatment CIN 2/3. 
In another woman, initially treated for a small CIN 3 lesion by
LLETZ, follow-up after treatment ended after 28 months because
Table 1 Characteristics of the 184 women included in the study 
Characteristic Number of patients 
n (%) 
High-risk HPV test at Positive 181 (98.4) 
initial treatment Negative 3 (1.6) 
Histology at time of CIN 2 9 (4.9) 
initial treatment CIN 3 175 (95.1) 
Treatment LLETZ 152 (82.6) 
Cone biopsy 32 (17.4) 
High-risk HPV test 3 months Positive 48 (26.1) 
after treatment Negative 136 (73.9) 
Cervical smear 3 months Abnormal 31 (16.8) 
after treatment Normal 153 (83.2) 
Follow-up Post-treatment CIN 2/3 29 (15.8) 
No evidence of disease 155 (84.2) 
Histology post-treatment CIN 2 9 (31.0) 
CIN 2/3 CIN 3/cancer* 20 (69.0) 
*One woman developed cervical cancer after initial treatment for CIN 3.798 MAE Nobbenhuis et al
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of a cervical smear read as Pap 4 (suspect for carcinoma in situ).
Subsequent colposcopy and biopsy showed cervical carcinoma.
The intermittent three cervical smears were read as normal. The
four high-risk HPV tests before the diagnosis of cervical cancer
were persistently positive for HPV type 16. Histology revealed an
undifferentiated small cell carcinoma of the cervix and she under-
went radical hysterectomy. 
Prediction of post-treatment CIN 2/3 
The high-risk HPV test and cervical smear results at different time-
points during follow-up of all participating women are shown in
Table 3. At the different time-points two subgroups of women were
compared, i.e. women who reached post-treatment CIN 2/3 during
follow-up and the remaining women. At 3, 6, 9 and 12 months post-
treatment more women with post-treatment CIN 2/3 would be iden-
tified by high-risk HPV testing than cervical cytology. 
The sensitivity for post-treatment CIN 2/3 among women with
a high-risk HPV-positive test or an abnormal cervical smear at 3
months after treatment was 93% vs 58%, respectively (at 6 months
90% vs 62%, at 9 months 90% vs 69%, at 12 months 90% vs 72%,
and at 24 months 93% vs 93%). Only at 3 and 6 months after treat-
ment was the sensitivity of a high-risk HPV-positive test signifi-
cantly higher than that of an abnormal cervical smear (McNemar test
P < 0.01, and P < 0.05, respectively). In women without post-
treatment CIN 2/3 the number of high-risk HPV-positive tests or
abnormal cervical smears at the different time-points was
comparable. 
The specificity of a positive high-risk HPV test or an abnormal
cervical smear at 3 months after treatment was 86% vs 91%,
respectively (at 6 months 92% vs 91%, at 9 months 96% vs 92%,
at 12 months 96% vs 95%, and at 24 months 99% vs 96%, respec-
tively). 
All 21 women with a high-risk HPV-positive test 3 months after
treatment without post-treatment CIN 2/3 cleared the HPV infec-
tion during follow-up (median 8 months, range 4–18 months).
Among them, 16 women with at least three normal cervical smears
returned to their general practitioner. In the remaining five women
a colposcopically directed biopsy was taken because of an
abnormal cervical smear. In two women no CIN was present, three
had a CIN 1 lesion (mild dysplasia). 
The negative predictive value of a high-risk HPV-negative, 
cytomorphologically normal, cervical smear was very high. At 3
months after treatment the negative predictive values of a high-risk
HPV-negative cytomorphologically normal smear, or either a high-
risk HPV-negative smear or a cytomorphologically normal smear
were 98%, 98% and 92%, respectively (at 6 months 99%, 98%, and
93%, and at 24 months 100%, 99% and 99% respectively). 
DISCUSSION 
Our results show that at 6 months after treatment for high-grade
CIN a positive high-risk HPV test is more predictive for post-
treatment CIN 2/3 than abnormal cervical cytology. The negative
predictive value of a high-risk HPV-negative cytomorphologically
normal cervical smear is very high and the presence of high-risk
HPV 24 months after treatment is a risk-factor for post-treatment
CIN 2/3. Therefore, we consider high-risk HPV testing valuable in
the early detection or prediction of post-treatment CIN 2/3. 
Three months after treatment only 26% of the women with a
high-risk HPV-positive test at baseline still had a positive high-risk
HPV test, indicating that in most women treatment resulted in
eradication of high-risk HPV. Cervical cytology was abnormal in
17% of the women, but it is known that reading cervical smears 3
months after ablative treatment is difficult because of the ‘repair-
effect’ (Maclean, 1984). 
The reason why some women present with post-treatment CIN
while the majority do not is unclear. Possible explanations include
incomplete removal of the CIN lesion, development of a new CIN
lesion by reinfection with HPV, and even the revival of so-called
dormant or occult HPV infections (Bistoletti et al, 1988; Nuovo
and Pedemonte, 1990). In 90% (26 of 29) of all cases with post-
treatment CIN 2/3 we found the same high-risk HPV type as
before the initial treatment. This high number agrees with other
studies (Chua et al, 1997). Since our HPV assay does not differen-
tiate between HPV type variants we cannot exclude a role for HPV
type variants in the genesis of post-treatment CIN 2/3. 
At 24 months of follow-up after treatment two out of the 155
(1.3%) women who did not develop post-treatment CIN 2/3 had a
positive high-risk HPV test with normal cytology. Since they both
had at least three normal cervical smears around the time of ac-
quisition of high-risk HPV they were regarded as having no high-
grade CIN lesion and were referred to their general practitioner
for screening according to the population-based screening
programme. So far, no recurrent CIN disease has been reported in
these women. 
The relation between a persistent high-risk HPV infection and
the development and maintenance of CIN lesions has already been
established (Ho et al, 1998; Nobbenhuis et al, 1999). Yet, in two
women with post-treatment CIN 2/3 no high-risk HPV type could
be found in the CIN lesion or corresponding smear (Table 2). HPV
negativity was confirmed by type-specific PCR. The occurrence of
high-risk HPV-negative scrapes in cases with cervical dysplasia is
in agreement with an earlier study (Nobbenhuis et al, 1999). 
Three facts argue for our view of using high-risk HPV testing,
next to cervical cytology, in the follow-up after initial treatment for
high-grade CIN lesions: the higher sensitivity of a high-risk HPV-
positive test than of an abnormal cervical smear, with similar
specificity; the high negative predictive value of a high-risk HPV-
negative, cytomorphologically normal cervical smear, and, largely
overlapping, partly different groups of women with post-treatment
CIN 2/3 were identified by HPV testing and cervical cytology. One
woman with cervical cancer and another with CIN 3 identified at
28 and 39 months after initial treatment, respectively, had normal
cervical smears during follow-up. They would not have been at
risk of undue referral to a low-risk group and follow-up procedure
if high-risk HPV testing was used to monitor the initial treatment,
since all intermittent high-risk HPV tests were positive. In these
patients, all cervical smears were revised by an expert panel and
were again read as normal. 
We advocate to monitor women 6 months after initial treatment
both by high-risk HPV testing and cervical cytology. In case of 
a positive test, colposcopically directed biopsies are indicated.
Retesting by both tests should be considered at 24 months after
initial treatment to avoid missing cervical carcinomas because of
detection problems. Moreover, it is known that acquisition of HPV
is increased in women with a history of CIN lesions (Nobbenhuis
et al, 1999). Only when cytological and HPV testing are negative during
at least 24 months should women be referred to the population-
based cervical cancer screening programme. These recommenda-
tions will be tested, together with a cost–benefit analysis, in a
prospective study involving women treated for high-grade CIN. ACKNOWLEDGEMENTS 
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